The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study

Stuart J. Connolly; Lars Wallentin; Michael D. Ezekowitz; John Eikelboom; Jonas Oldgren; Paul A. Reilly; Martina Brueckmann; Janice Pogue; Marco Alings; John V. Amerena; Alvaro Avezum; Iris Baumgartner; Andrzej J. Budaj; Jyh-Hong Chen; Antonio L. Dans; Harald Darius; Giuseppe Di Pasquale; Jorge Ferreira; Greg C. Flaker; Marcus D. Flather; Maria Grazia Franzosi; Sergey P. Golitsyn; David A. Halon; Hein Heidbuchel; Stefan H. Hohnloser; Kurt Huber; Petr Jansky; Gabriel Kamensky; Matyas Keltai; Sung Soon Kim; Chu-Pak Lau; Jean-Yves Le Heuzey; Basil S. Lewis; Lisheng Liu; John Nanas; Razali Omar; Prem Pais; Knud E. Pedersen; Leopoldo S. Piegas; Dimitar Raev; Pal J. Smith; Mario Talajic; Ru San Tan; Supachai Tanomsup; Lauri Toivonen; Dragos Vinereanu; Denis Xavier; Jun Zhu; Susan Q. Wang; Christine O. Duffy; Ellison Themeles; Salim Yusuf

doi:10.1161/CIRCULATIONAHA.112.001139

The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study

Stuart J. Connolly, Lars Wallentin, Michael D. Ezekowitz, John Eikelboom, Jonas Oldgren, Paul A. Reilly, Martina Brueckmann, Janice Pogue, Marco Alings, John V. Amerena, Alvaro Avezum, Iris Baumgartner, Andrzej J. Budaj, Jyh-Hong Chen, Antonio L. Dans, Harald Darius, Giuseppe Di Pasquale, Jorge Ferreira, Greg C. Flaker, Marcus D. FlatherMaria Grazia Franzosi, Sergey P. Golitsyn, David A. Halon, Hein Heidbuchel, Stefan H. Hohnloser, Kurt Huber, Petr Jansky, Gabriel Kamensky, Matyas Keltai, Sung Soon Kim, Chu-Pak Lau, Jean-Yves Le Heuzey, Basil S. Lewis, Lisheng Liu, John Nanas, Razali Omar, Prem Pais, Knud E. Pedersen, Leopoldo S. Piegas, Dimitar Raev, Pal J. Smith, Mario Talajic, Ru San Tan, Supachai Tanomsup, Lauri Toivonen, Dragos Vinereanu, Denis Xavier, Jun Zhu, Susan Q. Wang, Christine O. Duffy, Ellison Themeles, Salim Yusuf

Research output: Contribution to journal › Article › peer-review

205 Citations (SciVal)

Abstract

During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses.

Original language	English
Pages (from-to)	237-243
Number of pages	7
Journal	Circulation
Volume	128
Issue number	3
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.112.001139
Publication status	Published - 16 Jul 2013

Keywords

Dose-Response Relationship, Drug
Humans
Stroke
Aged
Hemorrhage
beta-Alanine
Antithrombins
Benzimidazoles
Hospitalization
Aged, 80 and over
Embolism
Treatment Outcome
Middle Aged
Follow-Up Studies
Atrial Fibrillation
Female
Male

Access to Document

10.1161/CIRCULATIONAHA.112.001139

Cite this

Connolly, S. J., Wallentin, L., Ezekowitz, M. D., Eikelboom, J., Oldgren, J., Reilly, P. A., Brueckmann, M., Pogue, J., Alings, M., Amerena, J. V., Avezum, A., Baumgartner, I., Budaj, A. J., Chen, J-H., Dans, A. L., Darius, H., Di Pasquale, G., Ferreira, J., Flaker, G. C., ... Yusuf, S. (2013). The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study. Circulation, 128(3), 237-243. https://doi.org/10.1161/CIRCULATIONAHA.112.001139

@article{16f5f58e1a4348ac8acc8e28b8c42d48,

title = "The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study",

abstract = "During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses.",

keywords = "Dose-Response Relationship, Drug, Humans, Stroke, Aged, Hemorrhage, beta-Alanine, Antithrombins, Benzimidazoles, Hospitalization, Aged, 80 and over, Embolism, Treatment Outcome, Middle Aged, Follow-Up Studies, Atrial Fibrillation, Female, Male",

author = "Connolly, {Stuart J.} and Lars Wallentin and Ezekowitz, {Michael D.} and John Eikelboom and Jonas Oldgren and Reilly, {Paul A.} and Martina Brueckmann and Janice Pogue and Marco Alings and Amerena, {John V.} and Alvaro Avezum and Iris Baumgartner and Budaj, {Andrzej J.} and Jyh-Hong Chen and Dans, {Antonio L.} and Harald Darius and {Di Pasquale}, Giuseppe and Jorge Ferreira and Flaker, {Greg C.} and Flather, {Marcus D.} and Franzosi, {Maria Grazia} and Golitsyn, {Sergey P.} and Halon, {David A.} and Hein Heidbuchel and Hohnloser, {Stefan H.} and Kurt Huber and Petr Jansky and Gabriel Kamensky and Matyas Keltai and Kim, {Sung Soon} and Chu-Pak Lau and {Le Heuzey}, Jean-Yves and Lewis, {Basil S.} and Lisheng Liu and John Nanas and Razali Omar and Prem Pais and Pedersen, {Knud E.} and Piegas, {Leopoldo S.} and Dimitar Raev and Smith, {Pal J.} and Mario Talajic and Tan, {Ru San} and Supachai Tanomsup and Lauri Toivonen and Dragos Vinereanu and Denis Xavier and Jun Zhu and Wang, {Susan Q.} and Duffy, {Christine O.} and Ellison Themeles and Salim Yusuf",

year = "2013",

month = jul,

day = "16",

doi = "10.1161/CIRCULATIONAHA.112.001139",

language = "English",

volume = "128",

pages = "237--243",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott, Williams and Wilkins",

number = "3",

}

Connolly, SJ, Wallentin, L, Ezekowitz, MD, Eikelboom, J, Oldgren, J, Reilly, PA, Brueckmann, M, Pogue, J, Alings, M, Amerena, JV, Avezum, A, Baumgartner, I, Budaj, AJ, Chen, J-H, Dans, AL, Darius, H, Di Pasquale, G, Ferreira, J, Flaker, GC, Flather, MD, Franzosi, MG, Golitsyn, SP, Halon, DA, Heidbuchel, H, Hohnloser, SH, Huber, K, Jansky, P, Kamensky, G, Keltai, M, Kim, SS, Lau, C-P, Le Heuzey, J-Y, Lewis, BS, Liu, L, Nanas, J, Omar, R, Pais, P, Pedersen, KE, Piegas, LS, Raev, D, Smith, PJ, Talajic, M, Tan, RS, Tanomsup, S, Toivonen, L, Vinereanu, D, Xavier, D, Zhu, J, Wang, SQ, Duffy, CO, Themeles, E & Yusuf, S 2013, 'The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study', Circulation, vol. 128, no. 3, pp. 237-243. https://doi.org/10.1161/CIRCULATIONAHA.112.001139

TY - JOUR

T1 - The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study

AU - Connolly, Stuart J.

AU - Wallentin, Lars

AU - Ezekowitz, Michael D.

AU - Eikelboom, John

AU - Oldgren, Jonas

AU - Reilly, Paul A.

AU - Brueckmann, Martina

AU - Pogue, Janice

AU - Alings, Marco

AU - Amerena, John V.

AU - Avezum, Alvaro

AU - Baumgartner, Iris

AU - Budaj, Andrzej J.

AU - Chen, Jyh-Hong

AU - Dans, Antonio L.

AU - Darius, Harald

AU - Di Pasquale, Giuseppe

AU - Ferreira, Jorge

AU - Flaker, Greg C.

AU - Flather, Marcus D.

AU - Franzosi, Maria Grazia

AU - Golitsyn, Sergey P.

AU - Halon, David A.

AU - Heidbuchel, Hein

AU - Hohnloser, Stefan H.

AU - Huber, Kurt

AU - Jansky, Petr

AU - Kamensky, Gabriel

AU - Keltai, Matyas

AU - Kim, Sung Soon

AU - Lau, Chu-Pak

AU - Le Heuzey, Jean-Yves

AU - Lewis, Basil S.

AU - Liu, Lisheng

AU - Nanas, John

AU - Omar, Razali

AU - Pais, Prem

AU - Pedersen, Knud E.

AU - Piegas, Leopoldo S.

AU - Raev, Dimitar

AU - Smith, Pal J.

AU - Talajic, Mario

AU - Tan, Ru San

AU - Tanomsup, Supachai

AU - Toivonen, Lauri

AU - Vinereanu, Dragos

AU - Xavier, Denis

AU - Zhu, Jun

AU - Wang, Susan Q.

AU - Duffy, Christine O.

AU - Themeles, Ellison

AU - Yusuf, Salim

PY - 2013/7/16

Y1 - 2013/7/16

N2 - During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses.

AB - During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses.

KW - Dose-Response Relationship, Drug

KW - Humans

KW - Stroke

KW - Aged

KW - Hemorrhage

KW - beta-Alanine

KW - Antithrombins

KW - Benzimidazoles

KW - Hospitalization

KW - Aged, 80 and over

KW - Embolism

KW - Treatment Outcome

KW - Middle Aged

KW - Follow-Up Studies

KW - Atrial Fibrillation

KW - Female

KW - Male

U2 - 10.1161/CIRCULATIONAHA.112.001139

DO - 10.1161/CIRCULATIONAHA.112.001139

M3 - Article

C2 - 23770747

VL - 128

SP - 237

EP - 243

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 3

ER -